Cargando…

The influence of NAFLD on the risk of atherosclerosis and cardiovascular diseases

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in developed countries and is associated with obesity, dyslipidaemia, diabetes, and metabolic syndrome. Atherosclerosis and cardiovascular diseases are also highly prevalent in this group of patients, due to the prese...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wójcik-Cichy, Kamila, Koślińska-Berkan, Ewa, Piekarska, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2018
Materias:	Review Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865905/ https://www.ncbi.nlm.nih.gov/pubmed/29594192 http://dx.doi.org/10.5114/ceh.2018.73155

Ejemplares similares

Efficacy and direct costs of chronic hepatitis C treatment with first generation NS3/4A protease inhibitors in a real life population
por: Piekarska, Anna, et al.
Publicado: (2016)

Expression of selected genes in liver biopsy specimens in relation to early virological response in patients with chronic hepatitis C with HCV mono- and HIV/HCV co-infection
por: Jabłonowska, Elżbieta, et al.
Publicado: (2013)

The prevalence and severity of 25-(OH)-vitamin D insufficiency in HCV infected and in HBV infected patients: a prospective study
por: Berkan-Kawińska, Aleksandra, et al.
Publicado: (2015)

Surveillance for portal hypertension in the course of liver cirrhosis
por: Piekarska, Anna, et al.
Publicado: (2018)

Control of HBV infection in HIV/HBV co-infected patients treated with antiretroviral therapy – experience of Lodz Centre
por: Wlazłowska, Ewelina, et al.
Publicado: (2022)

The Influence of Polyphenols on Atherosclerosis Development
por: Ziółkiewicz, Agnieszka, et al.
Publicado: (2023)

NAFLD and cardiovascular diseases: a clinical review
por: Kasper, Philipp, et al.
Publicado: (2020)

Recommendations for the management of non-alcoholic fatty liver disease (NAFLD)
por: Tomasiewicz, Krzysztof, et al.
Publicado: (2018)

NAFLD and cardiovascular disease
por: Martins, Elisabete, et al.
Publicado: (2018)

From NAFLD to Cardiovascular Disease. Is it (Still) the Metabolic Syndrome?
por: MUNTEANU, MIHAI ALEXANDRU, et al.
Publicado: (2014)

Dysregulated lipid metabolism links NAFLD to cardiovascular disease
por: Deprince, Audrey, et al.
Publicado: (2020)

NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations
por: Niederseer, David, et al.
Publicado: (2021)

Risk of cardiovascular disease and loss in life expectancy in NAFLD
por: Shang, Ying, et al.
Publicado: (2022)

Immunity, atherosclerosis and cardiovascular disease
por: Frostegård, Johan
Publicado: (2013)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †
por: Yamashita, Shizuya, et al.
Publicado: (2023)

Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease
por: Gaggini, Melania, et al.
Publicado: (2013)

Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets
por: Tanase, Daniela Maria, et al.
Publicado: (2021)

Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease
por: Jarmakiewicz-Czaja, Sara, et al.
Publicado: (2022)

Atherosclerosis and Cardiovascular Diseases in Progeroid Syndromes
por: Kato, Hisaya, et al.
Publicado: (2022)

From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications
por: Boccatonda, Andrea, et al.
Publicado: (2023)

Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases
por: Ji, Eunhye, et al.
Publicado: (2021)

Sex differences in the intestinal microbiome: interactions with risk factors for atherosclerosis and cardiovascular disease
por: Ahmed, Shamon, et al.
Publicado: (2021)

NAFLD and Chronic Kidney Disease
por: Marcuccilli, Morgan, et al.
Publicado: (2016)

Influence of genetically predicted autoimmune diseases on NAFLD
por: Xu, Min, et al.
Publicado: (2023)

Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV
por: Lonardo, Amedeo, et al.
Publicado: (2016)

Prevalence of hepatitis C virus infection in patients hospitalised for ischemic heart disease versus controls – PRO-CARDIO-C study
por: Piekarska, Anna, et al.
Publicado: (2019)

The association between rs1260326 with the risk of NAFLD and the mediation effect of triglyceride on NAFLD in the elderly Chinese Han population
por: Yuan, Fan, et al.
Publicado: (2022)

Immunity and early atherosclerosis in the course of systemic lupus erythematosus, mixed connective tissue disease and antiphospholipid syndrome
por: Haładyj, Ewa, et al.
Publicado: (2016)

NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk
por: Ballestri, Stefano, et al.
Publicado: (2017)

Hepatic HMOX1 Expression Positively Correlates with Bach-1 and miR-122 in Patients with HCV Mono and HIV/HCV Coinfection
por: Jabłonowska, Elżbieta, et al.
Publicado: (2014)

Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis
por: Diehl, Philipp, et al.
Publicado: (2015)

Lipid Biomarkers and Atherosclerosis—Old and New in Cardiovascular Risk in Childhood
por: Močnik, Mirjam, et al.
Publicado: (2023)

Mechanism of Development of Atherosclerosis and Cardiovascular Disease in Diabetes Mellitus
por: Katakami, Naoto
Publicado: (2018)

Application of Metabolomics to Epidemiological Studies of Atherosclerosis and Cardiovascular Disease
por: Iida, Miho, et al.
Publicado: (2019)

The Complex Tail of Circulating Sphingolipids in Atherosclerosis and Cardiovascular Disease
por: Zelnik, Iris D., et al.
Publicado: (2021)

The risk of atherosclerosis in patients with chronic kidney disease
por: Olechnowicz-Tietz, Sylwia, et al.
Publicado: (2013)

TyG index is positively associated with risk of CHD and coronary atherosclerosis severity among NAFLD patients
por: Zhao, Jianqi, et al.
Publicado: (2022)

Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles
por: Martínez‐Arranz, Ibon, et al.
Publicado: (2022)

Genetic and epigenetic factors determining NAFLD risk
por: Jonas, Wenke, et al.
Publicado: (2020)

The role of NAFLD in cardiometabolic disease: an update
por: Faasse, Sarah, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_831m06ahe06m84aao5sg0qu9mm